St. Jude finds clues to hearing loss from chemotherapy

MEMPHIS, Tenn. – Sept. 26, 2006 -- Children with cancer who suffer hearing loss due to the toxic effects of chemotherapy might one day be able to get their hearing back through pharmacological and gene therapy, thanks to work done with mouse models at St. Jude Children's Research Hospital. Mice with a variety of genetic mutations that disrupt different parts of the ear will also help scientists understand age-related hearing loss in adults, as well as hearing loss caused by long-term exposure to loud noise, according to the researchers.

The investigators took the first step toward these ambitious goals by identifying 17 families of mice whose offspring carry one or more of a variety of mutations that cause them to lose the ability to hear high-frequency sounds, according to Jian Zuo, Ph.D., associate member of the St. Jude Department of Developmental Neurobiology. Zuo is senior author of a report on this work that appears in the October issue of Hearing Research.

These models will help scientists understand what happens in the ears of children who suffer ototoxicity (toxic damage to the inner ear due to chemotherapy) and eventually, which genes are responsible for that damage. "Our ongoing study of these mouse models will advance understanding of age-related and noise-induced hearing loss in humans--such as long-term exposure to loud music--which are similar to the damage that occurs in children receiving chemotherapy," Zuo said.

The mouse models of hearing loss were produced by the Tennessee Mouse Genome Consortium, a group of institutions across Tennessee that includes universities, several medical research centers and a national laboratory.

The consortium used ENU, a chemical that causes random mutations in sperm of mice that were subsequently mated with females. Offspring of this mating carried mutations in one or more specific spots in their DNA, Zuo explained. The random mutations caused a variety of disruptions of normal functions. However, only some of the mutations were likely to cause hearing loss, and it was not known which mutation each mouse had. Therefore, the St. Jude team screened more than 1,800 mice from 285 families using an auditory brainstem responses test. This test determines whether a particular mouse can respond to high frequencies by recording electrical activity from the hearing nerve and other parts of the brain in response to brief, high-frequency sounds. The team identified 17 families that showed evidence of hearing loss. The investigators then determined the types of ear abnormalities the mice had. The goal was to find the genes involved in different aspects of hearing loss.

"Now that we've identified the various problems in the ear that can contribute to hearing loss in these models, we can work back and look for specific mutations in these animals," Zuo said. "That will let us link specific mutations to specific disruptions in the ear that cause hearing loss. The long-term goal is to try to manipulate or replace those genes in order to overcome those problems."

Individual mutations might disrupt the work of a cascade of genes that cooperate to construct certain nerves or sections of the inner ear that sense sound; that stimulation is then turned into electrical impulses that go to the hearing center of the brain. Understanding how a specific mutation disrupts that cascade might lead to ways to repair the damage, Zuo said.

For example, one type of damage that occurs in children whose hearing is damaged by chemotherapy is loss of hair cells in the inner part of the ear. These cells sprout extremely fine hairs that move in response to sound waves and set up the electrical impulse that goes into the brain. These are the same cells damaged in adults by prolonged exposure to loud noise. "In the future we'd like to be able to prevent the loss of these hair cells or trigger their re-growth with some form of pharmacological or gene therapy intervention," Zuo said.

Other authors of this study include Mohammad Habiby Kermany, Lisan Parker and Yun-Kai Guo (St. Jude); Darla Miller (Oak Ridge National Laboratory; Oak Ridge, Tenn.); and Douglas Swanson, Tai-June Yoo and Dan Goldowitz (University of Tennessee Health Science Center, Memphis). This work was supported in part by the National Institutes of Health, a UNCF/MERCK Postdoctoral Science Research Fellowship and ALSAC.

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization. For more information, please visit www.stjude.org.